<DOC>
	<DOCNO>NCT00486122</DOCNO>
	<brief_summary>The purpose study test hypothesis atomoxetine administer orally , day , dose 1.4 mg/kg/day approximately 6 week give morning superior placebo child ADHD .</brief_summary>
	<brief_title>Evaluation Continuous Symptom Treatment ADHD</brief_title>
	<detailed_description />
	<mesh_term>Attention Deficit Disorder Hyperactivity</mesh_term>
	<mesh_term>Atomoxetine Hydrochloride</mesh_term>
	<criteria>Patients must ADHD meet disease diagnostic criterion define DSMIVRevised Males female least 6 year old 12 year old prior visit 2 Patients must able swallow capsule Patients must normal intelligence judgment investigator . Normal intelligence define without evidence significant general intellectual deficit expect achieve score 70 formal IQ testing administer . Laboratory result must show significant abnormality ( significance define laboratory value require acute medical intervention , indicate serious medical illness , require medical evaluation judgment investigator ) Patients weigh less 20 kg great 65 kg study entry ( visit 1 ) Patients documented history bipolar I bipolar II disorder , psychosis Patients document autism , Asperger 's syndrome , pervasive developmental disorder . Other comorbid psychiatric disorder exclude provided diagnosis ADHD predate comorbid disorder , ADHD symptoms primary source impairment patient Patients take antipsychotic medication 4 week prior visit 1 eligible .</criteria>
	<gender>All</gender>
	<minimum_age>6 Years</minimum_age>
	<maximum_age>12 Years</maximum_age>
	<verification_date>June 2007</verification_date>
</DOC>